| ICIs | immune checkpoint inhibitors |
| IIH | ICI-induced hypophysitis |
| PitNETs | pituitary neuroendocrine tumors |
| PDL-1 | programmed cell death ligand 1 |
| FDA | Food and Drug Administration |
| CTLA-4 | cytotoxic T-lymphocyte-associated antigen 4 |
| LAG-3 | lymphocyte-activating gene-3 |
| PD-1 | programmed cell death protein 1 |
| APCs | antigen presenting cells |
| MHC | major histocompatibility complex |
| TCR | T-cell receptor |
| IRAK1 | interleukin-1 receptor-associated kinase 1 |
| LINH | lymphocytic infundibulo-neurohypophysitis |
| AVP | arginine vasopressin |
| irAEs | immune-related adverse events |
| ADCC | antibody-dependent cellular cytotoxicity |
| GNAL | guanine nucleotide-binding protein G (olf) subunit alpha |
| ITM2B | integral membrane protein 2B |
| ACTH | adrenocorticotropic hormone |
| POMC | Proopiomelanocortin |
| NK | natural killer |